Skip to content

Sinecatechins

Published: July 26, 2026Updated: July 26, 2026

Sinecatechins (Veregen) is a topical medication derived from green tea extract used for the treatment of genital and perianal warts caused by human papillomavirus (HPV). The exact mechanism by which it clears warts is not fully understood, though it has shown anti-oxidative activity in laboratory studies. This prescription medication is applied directly to the affected skin areas to help eliminate visible warts.

Quick summary

Sinecatechins is a topical green tea extract treatment for genital and perianal warts that helps clear HPV-related growths through a not fully understood mechanism.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

ATC
D06BB12
RxNorm
753346
Generic
Sinecatechins
Class
atc-d06
Brands
Veregen
Availability
rx
Lactation
unknown
Routes
topical
Forms
ointment
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Topical treatment of external genital and perianal warts in immunocompetent patients aged 18 years and older. It is not indicated for the treatment of warts inside the rectum, urethra, vagina, or cervix.

The precise mechanism of action for wart clearance is unknown. Sinecatechins is a botanical extract from Camellia sinensis (green tea) leaves containing catechins. In vitro studies demonstrated anti-oxidative activity, though the clinical significance of this finding is uncertain.

For external use only; avoid contact with eyes, nose, mouth, and open wounds. Wash hands before and after application. Application to broken or inflamed skin may increase irritation. Not recommended for use during pregnancy unless benefits outweigh risks. Efficacy and safety in immunocompromised patients have not been established. Treatment should be continued until complete clearance of all warts, typically up to 16 weeks.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy